{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:49:57Z","timestamp":1788914997551,"version":"build-2803163510"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370240"],"award-info":[{"award-number":["82370240"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Cardiac fibrosis, a common pathological outcome of various heart diseases including myocardial infarction (MI), is primarily driven by the activation and trans-differentiation of cardiac fibroblasts that demand substantial adenosine triphosphate production (ATP) for energy. Although sodium-glucose co-transporter 2 (SGLT2) inhibitors such as dapagliflozin have been shown to improve outcomes in heart failure, their direct impact on cardiac fibrosis, particularly through the modulation of fibroblast energy metabolism remains unexplored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>We employed an integrated strategy combining metabolomics and metabolic flux analysis to investigate metabolic reprogramming in cardiac fibroblasts under ischaemic conditions. Our findings confirmed that treatment with an SGLT2 inhibitor confers anti-fibrotic benefits post-MI. Multi-omics analysis identified a key metabolic pathway modulated in fibroblasts from SGLT2 inhibitor-treated mice under ischaemia: the conversion of N-acetyl-glutamate (NAcGlu) to fumarate, catalysed by argininosuccinate lyase (ASL). This pathway serves as a metabolic bridge linking the urea cycle to the tricarboxylic acid (TCA) cycle. Exogenous supplementation with either NAcGlu or fumarate significantly improved cardiac function and reduced fibrosis after MI. In contrast, targeted deletion of ASL in activated cardiac fibroblasts impaired cardiac performance, even with NAcGlu supplementation. Mechanistically, we found that fumarate accumulation under stress presses the TCA cycle in cardiac fibroblasts, resulting in reduced ATP production.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These findings identify the NAcGlu\/ASL\/fumarate axis as an important regulator of fibroblast metabolism and trans-differentiation during ischaemic stress. Our data are consistent with a model in which targeting key metabolites (NAcGlu, fumarate) or enzymes (ASL) in the urea cycle pathway of cardiac fibroblasts may point to a potential therapeutic strategy to combat adverse cardiac fibrosis following MI.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cvr\/cvag119","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T11:46:54Z","timestamp":1779882414000},"page":"1359-1373","source":"Crossref","is-referenced-by-count":2,"title":["Urea cycle fumarate limits fibrosis post-myocardial infarction by reducing fibroblast mitochondrial adenosine triphosphate production"],"prefix":"10.1093","volume":"122","author":[{"given":"Jing","family":"Zhao","sequence":"first","affiliation":[{"name":"Department of Cardiology of the Second Affiliated Hospital, School of Medicine, Zhejiang University , 88# Jiefang Road, Hangzhou, Zhejiang Province 310009 ,","place":["China"]},{"name":"State Key Laboratory of Transvascular Implantation Devices, 88# Jiefang Road, Hangzhou, Zhejiang Province 310009 ,","place":["China"]},{"name":"Heart Regeneration and Repair Key Laboratory of Zhejiang Province , 88# Jiefang Road, Hangzhou, Zhejiang Province 310009, China"},{"name":"Transvascular Implantation Devices Research Institute, Binjiang Institute of Zhejiang University, Building 2, Huoju Innovation Center, No. 239 Jucai Road, Changhe Subdistrict, Binjiang District, Hangzhou, Zhejiang Province 310053 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yating","family":"Ruan","sequence":"additional","affiliation":[{"name":"Department of Cardiology of the Second Affiliated Hospital, School of Medicine, Zhejiang University , 88# Jiefang Road, Hangzhou, Zhejiang Province 310009 ,","place":["China"]},{"name":"State Key Laboratory of Transvascular Implantation Devices, 88# Jiefang Road, Hangzhou, Zhejiang Province 310009 ,","place":["China"]},{"name":"Heart Regeneration and Repair Key Laboratory of Zhejiang Province , 88# Jiefang Road, Hangzhou, Zhejiang Province 310009, China"},{"name":"Transvascular Implantation Devices Research Institute, Binjiang Institute of Zhejiang University, Building 2, Huoju Innovation Center, No. 239 Jucai Road, Changhe Subdistrict, Binjiang District, Hangzhou, Zhejiang Province 310053 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjian","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The First Affiliated Hospital of Wenzhou Medical University , Wenzhou 325000 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiming","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Cardiology of the Second Affiliated Hospital, School of Medicine, Zhejiang University , 88# Jiefang Road, Hangzhou, Zhejiang Province 310009 ,","place":["China"]},{"name":"State Key Laboratory of Transvascular Implantation Devices, 88# Jiefang Road, Hangzhou, Zhejiang Province 310009 ,","place":["China"]},{"name":"Heart Regeneration and Repair Key Laboratory of Zhejiang Province , 88# Jiefang Road, Hangzhou, Zhejiang Province 310009, China"},{"name":"Transvascular Implantation Devices Research Institute, Binjiang Institute of Zhejiang University, Building 2, Huoju Innovation Center, No. 239 Jucai Road, Changhe Subdistrict, Binjiang District, Hangzhou, Zhejiang Province 310053 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Cardiology of the Second Affiliated Hospital, School of Medicine, Zhejiang University , 88# Jiefang Road, Hangzhou, Zhejiang Province 310009 ,","place":["China"]},{"name":"State Key Laboratory of Transvascular Implantation Devices, 88# Jiefang Road, Hangzhou, Zhejiang Province 310009 ,","place":["China"]},{"name":"Heart Regeneration and Repair Key Laboratory of Zhejiang Province , 88# Jiefang Road, Hangzhou, Zhejiang Province 310009, China"},{"name":"Transvascular Implantation Devices Research Institute, Binjiang Institute of Zhejiang University, Building 2, Huoju Innovation Center, No. 239 Jucai Road, Changhe Subdistrict, Binjiang District, Hangzhou, Zhejiang Province 310053 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linjun","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Cardiology of the Second Affiliated Hospital, School of Medicine, Zhejiang University , 88# Jiefang Road, Hangzhou, Zhejiang Province 310009 ,","place":["China"]},{"name":"State Key Laboratory of Transvascular Implantation Devices, 88# Jiefang Road, Hangzhou, Zhejiang Province 310009 ,","place":["China"]},{"name":"Heart Regeneration and Repair Key Laboratory of Zhejiang Province , 88# Jiefang Road, Hangzhou, Zhejiang Province 310009, China"},{"name":"Transvascular Implantation Devices Research Institute, Binjiang Institute of Zhejiang University, Building 2, Huoju Innovation Center, No. 239 Jucai Road, Changhe Subdistrict, Binjiang District, Hangzhou, Zhejiang Province 310053 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinghui","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Cardiology of the Second Affiliated Hospital, School of Medicine, Zhejiang University , 88# Jiefang Road, Hangzhou, Zhejiang Province 310009 ,","place":["China"]},{"name":"State Key Laboratory of Transvascular Implantation Devices, 88# Jiefang Road, Hangzhou, Zhejiang Province 310009 ,","place":["China"]},{"name":"Heart Regeneration and Repair Key Laboratory of Zhejiang Province , 88# Jiefang Road, Hangzhou, Zhejiang Province 310009, China"},{"name":"Transvascular Implantation Devices Research Institute, Binjiang Institute of Zhejiang University, Building 2, Huoju Innovation Center, No. 239 Jucai Road, Changhe Subdistrict, Binjiang District, Hangzhou, Zhejiang Province 310053 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liya","family":"Hou","sequence":"additional","affiliation":[{"name":"Department of Cardiology of the Second Affiliated Hospital, School of Medicine, Zhejiang University , 88# Jiefang Road, Hangzhou, Zhejiang Province 310009 ,","place":["China"]},{"name":"State Key Laboratory of Transvascular Implantation Devices, 88# Jiefang Road, Hangzhou, Zhejiang Province 310009 ,","place":["China"]},{"name":"Heart Regeneration and Repair Key Laboratory of Zhejiang Province , 88# Jiefang Road, Hangzhou, Zhejiang Province 310009, China"},{"name":"Transvascular Implantation Devices Research Institute, Binjiang Institute of Zhejiang University, Building 2, Huoju Innovation Center, No. 239 Jucai Road, Changhe Subdistrict, Binjiang District, Hangzhou, Zhejiang Province 310053 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Liao","sequence":"additional","affiliation":[{"name":"Department of Cardiology of the Second Affiliated Hospital, School of Medicine, Zhejiang University , 88# Jiefang Road, Hangzhou, Zhejiang Province 310009 ,","place":["China"]},{"name":"State Key Laboratory of Transvascular Implantation Devices, 88# Jiefang Road, Hangzhou, Zhejiang Province 310009 ,","place":["China"]},{"name":"Heart Regeneration and Repair Key Laboratory of Zhejiang Province , 88# Jiefang Road, Hangzhou, Zhejiang Province 310009, China"},{"name":"Transvascular Implantation Devices Research Institute, Binjiang Institute of Zhejiang University, Building 2, Huoju Innovation Center, No. 239 Jucai Road, Changhe Subdistrict, Binjiang District, Hangzhou, Zhejiang Province 310053 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deling","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of Cardiology of the Second Affiliated Hospital, School of Medicine, Zhejiang University , 88# Jiefang Road, Hangzhou, Zhejiang Province 310009 ,","place":["China"]},{"name":"State Key Laboratory of Transvascular Implantation Devices, 88# Jiefang Road, Hangzhou, Zhejiang Province 310009 ,","place":["China"]},{"name":"Heart Regeneration and Repair Key Laboratory of Zhejiang Province , 88# Jiefang Road, Hangzhou, Zhejiang Province 310009, China"},{"name":"Transvascular Implantation Devices Research Institute, Binjiang Institute of Zhejiang University, Building 2, Huoju Innovation Center, No. 239 Jucai Road, Changhe Subdistrict, Binjiang District, Hangzhou, Zhejiang Province 310053 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6978-987X","authenticated-orcid":false,"given":"Cheng","family":"Ni","sequence":"additional","affiliation":[{"name":"Department of Cardiology of the Second Affiliated Hospital, School of Medicine, Zhejiang University , 88# Jiefang Road, Hangzhou, Zhejiang Province 310009 ,","place":["China"]},{"name":"State Key Laboratory of Transvascular Implantation Devices, 88# Jiefang Road, Hangzhou, Zhejiang Province 310009 ,","place":["China"]},{"name":"Heart Regeneration and Repair Key Laboratory of Zhejiang Province , 88# Jiefang Road, Hangzhou, Zhejiang Province 310009, China"},{"name":"Transvascular Implantation Devices Research Institute, Binjiang Institute of Zhejiang University, Building 2, Huoju Innovation Center, No. 239 Jucai Road, Changhe Subdistrict, Binjiang District, Hangzhou, Zhejiang Province 310053 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"key":"2026071113023384400_cvag119-B1","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.jacc.2012.03.074","article-title":"Cardiovascular disease in the developing world: prevalences, patterns, and the potential of early disease detection","volume":"60","author":"Celermajer","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2026071113023384400_cvag119-B2","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/cvr\/cvaa324","article-title":"Cardiac fibrosis","volume":"117","author":"Frangogiannis","year":"2021","journal-title":"Cardiovasc Res"},{"key":"2026071113023384400_cvag119-B3","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S0735-1097(99)00630-0","article-title":"Cardiac remodeling\u2013concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling","volume":"35","author":"Cohn","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"2026071113023384400_cvag119-B4","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1161\/01.CIR.76.1.44","article-title":"Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction","volume":"76","author":"White","year":"1987","journal-title":"Circulation"},{"key":"2026071113023384400_cvag119-B5","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.phrs.2008.06.007","article-title":"The immune system and cardiac repair","volume":"58","author":"Frangogiannis","year":"2008","journal-title":"Pharmacol Res"},{"key":"2026071113023384400_cvag119-B6","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/s41392-022-01070-3","article-title":"Targeting fibrosis, mechanisms and cilinical trials","volume":"7","author":"Zhao","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"2026071113023384400_cvag119-B7","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMcp0909392","article-title":"Clinical practice. Systolic heart failure","volume":"362","author":"McMurray","year":"2010","journal-title":"N Engl J Med"},{"key":"2026071113023384400_cvag119-B8","doi-asserted-by":"crossref","first-page":"121033","DOI":"10.1016\/j.lfs.2022.121033","article-title":"Advances in energy metabolism in renal fibrosis","volume":"312","author":"Wei","year":"2023","journal-title":"Life Sci"},{"key":"2026071113023384400_cvag119-B9","doi-asserted-by":"crossref","first-page":"L544","DOI":"10.1152\/ajplung.00521.2017","article-title":"Metabolic reprogramming in the pathogenesis of chronic lung diseases, including BPD, COPD, and pulmonary fibrosis","volume":"314","author":"Zhao","year":"2018","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"2026071113023384400_cvag119-B10","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.4161\/cc.25695","article-title":"Oncogenes induce the cancer-associated fibroblast phenotype: metabolic symbiosis and \u201cfibroblast addiction\u201d are new therapeutic targets for drug discovery","volume":"12","author":"Lisanti","year":"2013","journal-title":"Cell Cycle"},{"key":"2026071113023384400_cvag119-B11","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ejca.2019.09.002","article-title":"Metabolic crosstalk in the breast cancer microenvironment","volume":"121","author":"Dias","year":"2019","journal-title":"Eur J Cancer"},{"key":"2026071113023384400_cvag119-B12","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1161\/CIRCRESAHA.119.311148","article-title":"The extracellular matrix in ischemic and nonischemic heart failure","volume":"125","author":"Frangogiannis","year":"2019","journal-title":"Circ Res"},{"key":"2026071113023384400_cvag119-B13","doi-asserted-by":"crossref","first-page":"e148554","DOI":"10.1172\/JCI148554","article-title":"Therapeutic targets for cardiac fibrosis: from old school to next-gen","volume":"132","author":"Travers","year":"2022","journal-title":"J Clin Invest"},{"key":"2026071113023384400_cvag119-B14","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.jacc.2019.11.036","article-title":"Clinical benefit of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-art review","volume":"75","author":"Zelniker","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026071113023384400_cvag119-B15","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"2026071113023384400_cvag119-B16","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"2026071113023384400_cvag119-B17","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"2026071113023384400_cvag119-B18","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"2026071113023384400_cvag119-B19","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/j.jacc.2019.01.056","article-title":"Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics","volume":"73","author":"Santos-Gallego","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026071113023384400_cvag119-B20","doi-asserted-by":"crossref","first-page":"e013389","DOI":"10.1161\/JAHA.119.013389","article-title":"SGLT-2 inhibitors in heart failure: current management, unmet needs, and therapeutic prospects","volume":"8","author":"Lam","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"2026071113023384400_cvag119-B21","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12933-021-01237-2","article-title":"Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: the EMPACEF study","volume":"20","author":"Gaborit","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"2026071113023384400_cvag119-B22","doi-asserted-by":"crossref","first-page":"708177","DOI":"10.3389\/fphar.2021.708177","article-title":"A SGLT2 inhibitor dapagliflozin alleviates diabetic cardiomyopathy by suppressing high glucose-induced oxidative stress in vivo and in vitro","volume":"12","author":"Xing","year":"2021","journal-title":"Front Pharmacol"},{"key":"2026071113023384400_cvag119-B23","doi-asserted-by":"crossref","first-page":"101334","DOI":"10.1016\/j.xcrm.2023.101334","article-title":"Dapagliflozin protects against chronic heart failure in mice by inhibiting macrophage-mediated inflammation, independent of SGLT2","volume":"4","author":"Wu","year":"2023","journal-title":"Cell Rep Med"},{"key":"2026071113023384400_cvag119-B24","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41392-024-01816-1","article-title":"2-APQC, a small-molecule activator of Sirtuin-3 (SIRT3), alleviates myocardial hypertrophy and fibrosis by regulating mitochondrial homeostasis","volume":"9","author":"Peng","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"2026071113023384400_cvag119-B25","doi-asserted-by":"crossref","first-page":"4757","DOI":"10.1038\/s41467-024-48970-2","article-title":"Semaglutide ameliorates cardiac remodeling in male mice by optimizing energy substrate utilization through the Creb5\/NR4a1 axis","volume":"15","author":"Ma","year":"2024","journal-title":"Nat Commun"},{"key":"2026071113023384400_cvag119-B26","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.2337\/dc16-0542","article-title":"Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis","volume":"39","author":"Mudaliar","year":"2016","journal-title":"Diabetes Care"},{"key":"2026071113023384400_cvag119-B27","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.2337\/db15-1356","article-title":"Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes","volume":"65","author":"Ferrannini","year":"2016","journal-title":"Diabetes"},{"key":"2026071113023384400_cvag119-B28","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1111\/dom.13577","article-title":"Sodium-glucose cotransporter 2 inhibitors regulate ketone body metabolism via inter-organ crosstalk","volume":"21","author":"Kim","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"2026071113023384400_cvag119-B29","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/s10038-019-0614-4","article-title":"Urea cycle disorders-update","volume":"64","author":"Matsumoto","year":"2019","journal-title":"J Hum Genet"},{"key":"2026071113023384400_cvag119-B30","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/s41568-018-0054-z","article-title":"Rewiring urea cycle metabolism in cancer to support anabolism","volume":"18","author":"Keshet","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"2026071113023384400_cvag119-B31","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/s44161-024-00502-3","article-title":"Nuclear ATP-citrate lyase regulates chromatin-dependent activation and maintenance of the myofibroblast gene program","volume":"3","author":"Lazaropoulos","year":"2024","journal-title":"Nat Cardiovasc Res"},{"key":"2026071113023384400_cvag119-B32","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1038\/s41401-021-00830-1","article-title":"Aminoacylase-1 plays a key role in myocardial fibrosis and the therapeutic effects of 20(S)-ginsenoside Rg3 in mouse heart failure","volume":"43","author":"Lai","year":"2022","journal-title":"Acta Pharmacol Sin"},{"key":"2026071113023384400_cvag119-B33","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1038\/s44161-024-00531-y","article-title":"\u03b1-Ketoglutarate promotes cardiomyocyte proliferation and heart regeneration after myocardial infarction","volume":"3","author":"Shi","year":"2024","journal-title":"Nat Cardiovasc Res"},{"key":"2026071113023384400_cvag119-B34","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1038\/s41591-024-03169-2","article-title":"The traditional Chinese medicine Qiliqiangxin in heart failure with reduced ejection fraction: a randomized, double-blind, placebo-controlled trial","volume":"30","author":"Cheang","year":"2024","journal-title":"Nat Med"},{"key":"2026071113023384400_cvag119-B35","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300286","article-title":"Dapagliflozin in myocardial infarction without diabetes or heart failure","volume":"3","author":"James","year":"2024","journal-title":"NEJM Evid"},{"key":"2026071113023384400_cvag119-B36","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jacasi.2022.02.004","article-title":"Effects of dapagliflozin in Asian patients with heart failure and reduced ejection fraction in DAPA-HF","volume":"2","author":"Docherty","year":"2022","journal-title":"JACC Asia"}],"container-title":["Cardiovascular Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cardiovascres\/advance-article-pdf\/doi\/10.1093\/cvr\/cvag119\/68428545\/cvag119.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cardiovascres\/article-pdf\/122\/10\/1359\/68428545\/cvag119.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cardiovascres\/article-pdf\/122\/10\/1359\/68428545\/cvag119.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T17:02:47Z","timestamp":1783789367000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cardiovascres\/article\/122\/10\/1359\/8697713"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":36,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,5,28]]},"published-print":{"date-parts":[[2026,7,11]]}},"URL":"https:\/\/doi.org\/10.1093\/cvr\/cvag119","relation":{},"ISSN":["0008-6363","1755-3245"],"issn-type":[{"value":"0008-6363","type":"print"},{"value":"1755-3245","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,5,28]]}}}